ANI Pharmaceuticals, Inc. (ANIP)

Market Cap	1.31B
Revenue (ttm)	674.07M
Net Income (ttm)	-22.43M
Shares Out	20.02M
EPS (ttm)	-1.15
PE Ratio	n/a
Forward PE	10.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	203,910
Open	64.76
Previous Close	63.56
Day's Range	64.76 - 65.42
52-Week Range	52.50 - 77.00
Beta	0.55
Analysts	Strong Buy
Price Target	80.13 (+22.8%)
Earnings Date	Aug 5, 2025

About ANIP

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group pu...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 897
• Stock Exchange: NASDAQ
• Ticker Symbol: ANIP
• Website: https://www.anipharmaceuticals.com

Analyst Summary

According to 8 analysts, the average rating for ANIP stock is "Strong Buy." The 12-month stock price target is $80.13, which is an increase of 22.80% from the latest price.

Price Target

$80.13

(22.80% upside)

Analyst Consensus: Strong Buy